Results 141 to 150 of about 4,520 (170)

Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis

Annals of Medicine, 2022
Jiake Tang, Chunyi Wang, Yongran Cheng   +2 more
exaly  

Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID‐19: A rapid review and meta‐analysis

Journal of Medical Virology, 2023
Bahman Amani
exaly  

Paxlovid for hospitalized COVID-19 patients with chronic kidney disease

Antiviral Research, 2023
Jiayi Yan, Yaping Zhan, Zhenyuan Li
exaly  

Cholesterol-lowering Drugs for High-Risk Hypercholesterolemia Patients with COVID-19 While on Paxlovid™ Therapy

Future Virology, 2022
Alpo Vuorio, Petri T Kovanen, Frederick J Raäl   +2 more
exaly  

Barriers to Worldwide Access for Paxlovid, a New Treatment for COVID-19

Open Forum Infectious Diseases, 2022
Toby Pepperrell, Leah Ellis, Junzheng Wang   +2 more
exaly  

Paxlovid (nirmatrelvir/ritonavir).

WMJ : official publication of the State Medical Society of Wisconsin, 2022
Kristin, Busse, Abir T, El-Alfy
openaire   +1 more source

Postmarketing Reporting of Paxlovid‐Related Dysgeusia: A Real‐World Pharmacovigilance Study

Otolaryngology - Head and Neck Surgery, 2023
David J Cvancara, Hans C Baertsch, Ashton E Lehmann   +2 more
exaly  

Paxlovid for a patient on DOAC

2022
openaire   +1 more source

Proxalutamide for the treatment of COVID‐19 rebound following Paxlovid treatment: Report of four cases and review of the literature

Journal of Clinical Laboratory Analysis, 2023
Min-Jie Ju, Xiao-Dan Wang, Hao Fang
exaly  

Efficacy and safety of paxlovid (nirmatrelvir/ritonavir) in the treatment of COVID‐19: An updated meta‐analysis and trial sequential analysis

Reviews in Medical Virology, 2023
Haokun Tian, Tiangang Song
exaly